Hina Chaudhry, MD
Sleep Medicine · Charleston, SCNPI 1518259977
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $704 and has fallen 87.2% since, to $90 in 2025.
Across 113 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$335
- Electromed, Inc.$183
- Takeda Pharmaceuticals U.S.A., Inc.$181
- Sanofi$147
- AstraZeneca$136
- Boehringer Ingelheim$133
- plus $738 from 16 others
What the payments were for
- Food & beverage$1,852100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 23 | $335 |
| Electromed, Inc. | 14 | $183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $181 |
| Sanofi | 7 | $147 |
| AstraZeneca | 10 | $136 |
| Boehringer Ingelheim | 8 | $133 |
| Baxter Healthcare | 5 | $113 |
| Mylan Specialty L.p. | 5 | $95 |
| Regeneron Healthcare Solutions, Inc. | 4 | $84 |
| Philips North America LLC | 4 | $72 |
| Grifols USA, LLC | 4 | $69 |
| Merck | 4 | $65 |
| Mallinckrodt Enterprises LLC | 4 | $57 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| AbbVie | 2 | $26 |
| Resmed Corp | 1 | $23 |
| Novo Nordisk | 1 | $21 |
| Circassia Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Insmed, Inc. | 1 | $14 |
How this compares
$1,852 in reported general payments places this provider in the 55th percentile of 25 sleep medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $121,557 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 121 | $96,865 |
| Dupixent PenDupilumab | 16 | $71,951 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $26,877 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $22,004 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $17,973 |
| Spiriva RespimatTiotropium Bromide | 16 | $17,258 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $16,685 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $8,237 |
| Wixela InhubFluticasone Propion/Salmeterol | 63 | $7,744 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $7,104 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $6,398 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $6,348 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,087 |
| DuleraMometasone/Formoterol | 12 | $3,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $335 | $152,094237 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $181 | $121,55713 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $136 | $41,05691 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $133 | $23,34429 claims |
| MerckDulera | $65 | $3,87212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 25 sleep medicine providers in South Carolina.
Other sleep medicine in Charleston
- Meher FarooqCharleston$3K
- Andrea RinnCharleston$371
- Megan BrunckhorstCharleston$198
- Robert VoronaCharleston$110
- Wendy Lyn EstrelladoCharleston$93
- Luminita TudorCharleston$50
- William HollinsColumbia$147K
- Luis de la CruzSpartanburg$20K
- Rodney HarrisonColumbia$14K
- Terry GraingerColumbia$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.